Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide.
Between 1971 and 1979, seventy-four patients with metastatic or advanced recurrent sarcoma of uterine origin were treated with combination chemotherapy consisting of vincristine, actinomycin D, and cyclophosphamide (Cytoxan). The probability of survival at 2 and 5 years was 23 and 15%, respectively. The response rate for patients with measurable disease was 28.9% (15.6% partial responses and 13.3% complete responses). The median duration of a complete response was 16 months and that of a partial response was 5.5 months. The median survival of the complete responders was prolonged when compared to nonresponders.